








Anixa Biosciences is a clinical-stage biotechnology company developing first-in-class products for cancer treatment and prevention.

The Company's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.

By partnering with world-renowned research institutions on all stages of development, Anixa maintains a capital-efficient and low-cost business model that facilitates ongoing identification and examination of emerging technologies for potential development and commercialization.

Key Programs & Development Partnerships

THERAPEUTIC AREA	MECHANISM OF ACTION	INDICATION	GEOGRAPHIC RIGHTS	STAGE	UPCOMING MILESTONES	PARTNERS
Oncology	CAR-T Therapeutic	Ovarian Cancer / Other Solid Tumors	Global	<u>Phase 1</u>	Periodic data releases (enrollment based)	 
Oncology	Vaccine Therapeutic	Breast Cancer	Global	<u>Phase 1 completed</u>	Phase 2 enrollment	 
Oncology	Vaccine	Ovarian Cancer	Global	Pre-clinical	Initiate IND enabling studies	 
Oncology	Vaccine	Lung, Colon, Prostate	Global	R&D	Pre-clinical Data	

Investment Highlights

Robust pipeline in oncology/immunology. Multiple value-creating catalysts for clinical programs over next 12 months.

Positive Phase 1 clinical data. Breast cancer vaccine: 74% of women showed immune responses, with responses observed at all dose levels, and no safety issues. Ovarian cancer CAR-T therapy: no dose-limiting toxicities observed, and improvements in quality of life and overall survival in multiple patients.

Strong financial profile and clean capital structure. Capital-efficient, low-cost business model with research support from key partners. ~\$5-7M annual cash burn since 2017. Cash and equivalents of \$14M and \$0 debt (1/31/26). 33M common shares outstanding, no preferred shares, and no warrants.

High-value partnerships. Licensing, funding, and collaboration with top-tier, world-renowned research organizations and institutions.

Significant TAM opportunity. 1 in 8 women will have breast cancer in their lives. ~3.8M breast cancer survivors¹. ~230,000 women living with ovarian cancer¹. All women potentially eligible for vaccines: ~168M in the U.S.

Proven management and board. Decades of success in starting, building, managing, and investing in technology-related companies. Scientific advisory from renowned doctors in oncology research.

¹National Cancer Institute.

Science – Vaccines

Imagine if the immune system could be trained to kill cancer cells as they arise before they form into tumors. Perhaps, this could eliminate the onset of cancer. The challenge for scientists has been to identify an agent that allows the immune system to target malignant cells without harming healthy tissue. Anixa partner Cleveland Clinic has identified such protein agents.

Breast Cancer—Alpha-lactalbumin

- Present in healthy breast tissue during lactation.
- Disappears after a woman stops nursing her child.
- Presents in many types of breast cancer.

By developing a vaccine that targets alpha-lactalbumin, Anixa believes the immune system can destroy breast cancer cells as they arise and ultimately prevent tumors from forming.

Science – CAR-T

Anixa's ovarian cancer CAR-T therapy, lira-cel, has three distinct differentiators from other CAR-T therapies: 1) it has a unique target, Follicle Stimulating Hormone Receptor (FSHR), which is only expressed in ovaries and no other healthy organ in the body, 2) FSHR is expressed in the blood vessels of tumors, thus allowing lira-cel to act as an anti-angiogenic treatment in addition to the direct targeting effect on the ovarian cancer cells, and 3) the therapy is administered via Intra Peritoneal delivery, allowing for better trafficking to the tumor lesions and a potentially safer approach.

Recent News

- *Apr 1, 2026: [Anixa Biosciences Announces Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results: Cytovance Selected for cGMP Manufacturing](#)*
- *Mar 9, 2026: [Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property \(MOIP\) for Patent Covering Breast Cancer Vaccine Technology](#)*
- *Feb 9, 2026: [Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation](#)*

Leadership Team



AMIT KUMAR, PH.D., *Chairman & Chief Executive Officer*

Investor, founder, director and CEO of several technology enterprises, both public and private. CombiMatrix Corporation, OAK Investment Partners, Acacia Research Corporation, former American Cancer Society board member.



MICHAEL CATELANI, *President, COO & CFO*

Seasoned executive with over 30 years of finance and operations management experience. Tacere Therapeutics, Benitec Biopharma, Axon Instruments, Ernst & Young.



PAMELA D. GARZONE, PH.D., *Chief Development Officer*

Senior pharmaceutical executive with over 25 years of strategic, scientific, clinical and regulatory leadership in drug development. Calibr/Scripps Research Institute, Pfizer, Elan Pharmaceuticals, Genetics Institute, Genentech.

Market Snapshot*

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
\$2.55 (4/2/26)	\$2.33 - \$5.46	162K	33.5M	\$85.5M

Analyst coverage:

Yi Chen, PhD, **H.C. Wainwright** / Jason Kolbert, **D. Boral Capital**
Jason McCarthy, PhD, **Maxim Group** / Ilya Zubkov, **Freedom Capital Markets**

Contact

3150 Almaden Expressway, Suite 250
San Jose, CA 95118

Mike Catelani, President, COO & CFO
(408) 708-9808 - mcatelani@anixa.com

*Price and volume quotes from Yahoo! Finance

Forward-Looking Statements Disclaimer: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences' current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A – Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.